EGFR and non-small cell lung carcinoma: Icotinib, another first-generation EGFR tyrosine kinase inhibitor, was also recently assessed against platinum-based doublet chemotherapy as adjuvant treatment for completely resected, EGFR-mutated, stage II to IIIA NSCLC (as per the 7th edition of the AJCC staging system) in a Chinese, multicenter, phase 3 randomized trial (EVIDENCE) (13).